2m 2m 2m 2m 2m 2m 2m
TSCAN THERAPEUT (TCRX)
NASDAQ
$0.96-$0.02 (-1.65%)
Price as of Jun 03, 2026 6:43 PM EDT- $66.0MMarket Cap
- -44.00%1-Year Change
- BiotechnologyIndustry
TSCAN THERAPEUT (TCRX)
$0.96-$0.02 (-1.65%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 10.3M +266.65% | 2.8M -86.62% | 21.0M +55.52% | 13.5M +33.47% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 10.3M +266.65% | 2.8M -86.62% | 21.0M +55.52% | 13.5M +33.47% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -114.2M +6.33% | -107.3M +21.78% | -88.2M +47.37% | -59.8M +33.07% | |
Depreciation and Amortization Expense | 2.9M -30.23% | 4.1M -23.37% | 5.4M +4.36% | 5.1M +54.36% | |
Total Operating Expenses | 146.1M +6.18% | 137.6M +20.20% | 114.5M +42.83% | 80.2M +36.39% | |
Operating Profit | -135.8M +0.74% | -134.8M +44.26% | -93.5M +40.25% | -66.6M +37.00% | |
Interest Income | 8.8M -26.93% | 12.1M +50.83% | 8.0M +402.77% | 1.6M N/A | |
Interest Expense | -2.8M -24.20% | -3.7M -2.82% | -3.8M +219.64% | -1.2M N/A | |
Interest Income and Expense and Net | 6.0M -28.11% | 8.4M +98.40% | 4.2M +921.69% | 415,000 N/A | |
Total Nonoperating Income and Expense | 6.0M -17.41% | 7.3M +72.69% | 4.2M +921.69% | 415,000 N/A | |
Income before Taxes | -135.8M +0.74% | -134.8M +44.26% | -93.5M +40.25% | -66.6M +37.00% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -129.8M +1.78% | -127.5M +42.91% | -89.2M +34.73% | -66.2M +36.19% | |
Net Income from Continuing Operations Applicable to Common | -129.8M +1.78% | -127.5M +42.91% | -89.2M +34.73% | -66.2M +36.19% | |
Basic EPS and Net Income | -1.00 -12.28% | -1.14 -16.18% | -1.36 -50.55% | -2.75 -34.05% | |
Diluted EPS and Net Income | -1.00 -12.28% | -1.14 -16.18% | -1.36 -50.55% | -2.75 -34.05% | |
Basic Weighted Average Shares | 129.8M +15.88% | 112.0M +70.72% | 65.6M +172.78% | 24.0M +106.20% | |
Diluted Weighted Average Shares | 129.8M +15.88% | 112.0M +70.72% | 65.6M +172.78% | 24.0M +106.20% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 152.4M -14.71% | 178.7M +33.99% | 133.4M +11.11% | 120.0M -25.64% | |
Short-Term Investments | 111.4M 0.00% | 111.4M +89.86% | 58.7M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 263.8M -9.06% | 290.1M +51.06% | 192.0M +60.00% | 120.0M -25.64% | |
Total Current Assets | 157.2M -46.29% | 292.7M +50.70% | 194.2M +56.48% | 124.1M -25.07% | |
Accumulated Depreciation | 21.6M +15.32% | 18.7M +28.14% | 14.6M +42.83% | 10.2M +101.06% | |
Property and Plant and Equipment and Net | 8.7M +20.22% | 7.2M -6.46% | 7.7M -23.35% | 10.1M -14.15% | |
Total Long-Term Assets | 8.7M +20.22% | 7.2M -6.46% | 7.7M -23.35% | 10.1M -14.15% | |
Total Assets | 228.8M -38.35% | 371.1M +36.37% | 272.1M +36.70% | 199.1M +5.84% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 3.3M 0.00% | 3.3M N/A | N/A N/A | |
Total Current Liabilities | 18.7M -48.01% | 36.0M +20.58% | 29.8M +72.32% | 17.3M -18.92% | |
Total Long-Term Debt | 32.5M +1.44% | 32.1M +20.12% | 26.7M -8.84% | 29.3M N/A | |
Total Long-Term Liabilities | 135,000 0.00% | 135,000 +175.51% | 49,000 0.00% | 49,000 -49.48% | |
Total Liabilities | 105.7M -18.81% | 130.1M +7.31% | 121.3M +21.70% | 99.7M +264.66% | |
Retained Earnings | -504.9M +34.60% | -375.1M +51.49% | -247.6M +56.33% | -158.4M +71.86% | |
Total Stockholders Equity | 123.1M -48.91% | 241.0M +59.72% | 150.9M +51.73% | 99.4M -38.15% | |
Total Shares Outstanding | 52.6M -53.50% | 113.2M +18.32% | 95.7M +97.43% | 48.5M +1.33% | |
Cash Flow | |||||
Cash from Operating Activities | -135.3M +22.10% | -110.8M +80.62% | -61.4M -7.74% | -66.5M +36.62% | |
Capital Expenditures | 4.4M +15.22% | 3.8M +21.58% | 3.1M -25.54% | 4.2M -57.50% | |
Cash from Investing Activities | 109.4M +307.88% | -52.6M -13.41% | -60.8M +1,338.08% | -4.2M -57.50% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -336,000 -100.16% | 208.8M +54.13% | 135.4M +361.38% | 29.4M -84.52% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -1,315.38% -72.53% | -4,787.68% +978.30% | -444.00% -9.81% | -492.32% N/A | |
Return on Assets | -43.26% +9.13% | -39.64% +4.69% | -37.87% +10.70% | -34.21% N/A | |
Return on Equity | -71.28% +9.53% | -65.08% -8.71% | -71.29% +40.06% | -50.90% N/A | |
Revenue Growth | 266.65% +407.84% | -86.62% -256.03% | 55.52% +65.88% | 33.47% N/A | |
Current Ratio | 8.41 +3.29% | 8.14 +24.99% | 6.51 -9.19% | 7.17 N/A | |
Cash Ratio | 8.15 +64.04% | 4.97 +11.13% | 4.47 -35.52% | 6.94 N/A | |
Debt-to-Equity Ratio | N/A N/A | 0.15 -26.20% | 0.20 N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | 0.10 -13.59% | 0.11 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow